Sigrid Sandner1,2, Björn Redfors3, Dominick J Angiolillo4, Katia Audisio5, Stephen E Fremes6,7, Paul W A Janssen8, Alexander Kulik9, Roxana Mehran10, Joyce Peper8, Marc Ruel11, Jacqueline Saw12,13, Giovanni Jr Soletti5, Andrew Starovoytov12, Jurrien M Ten Berg8, Laura M Willemsen8, Qiang Zhao14, Yunpeng Zhu14, Mario Gaudino5. 1. Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria. 2. Weill Cornell Medicine, New York, New York. 3. Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden. 4. Division of Cardiology, University of Florida College of Medicine, Jacksonville. 5. Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, New York. 6. Schulich Heart Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada. 7. Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. 8. Department of Cardiology, St Antonius Hospital, Nieuwegein, the Netherlands. 9. Division of Cardiac Surgery, Boca Raton Regional Hospital and Florida Atlantic Hospital, Boca Raton. 10. Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York. 11. Division of Cardiac Surgery, University of Ottawa Heart Institute, Ottawa, Ontario, Canada. 12. Division of Cardiology, Vancouver General Hospital, British Columbia, Canada. 13. Division of Cardiology St Paul's Hospital, University of British Columbia, Vancouver, Canada. 14. Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Abstract
Importance: The role of ticagrelor with or without aspirin after coronary artery bypass graft surgery remains unclear. Objective: To compare the risks of vein graft failure and bleeding associated with ticagrelor dual antiplatelet therapy (DAPT) or ticagrelor monotherapy vs aspirin among patients undergoing coronary artery bypass graft surgery. Data Sources: MEDLINE, Embase, and Cochrane Library databases from inception to June 1, 2022, without language restriction. Study Selection: Randomized clinical trials (RCTs) comparing the effects of ticagrelor DAPT or ticagrelor monotherapy vs aspirin on saphenous vein graft failure. Data Extraction and Synthesis: Individual patient data provided by each trial were synthesized into a combined data set for independent analysis. Multilevel logistic regression models were used. Main Outcomes and Measures: The primary analysis assessed the incidence of saphenous vein graft failure per graft (primary outcome) in RCTs comparing ticagrelor DAPT with aspirin. Secondary outcomes were saphenous vein graft failure per patient and Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding events. A supplementary analysis included RCTs comparing ticagrelor monotherapy with aspirin. Results: A total of 4 RCTs were included in the meta-analysis, involving 1316 patients and 1668 saphenous vein grafts. Of the 871 patients in the primary analysis, 435 received ticagrelor DAPT (median age, 67 years [IQR, 60-72 years]; 65 women [14.9%]; 370 men [85.1%]) and 436 received aspirin (median age, 66 years [IQR, 61-73 years]; 63 women [14.5%]; 373 men [85.5%]). Ticagrelor DAPT was associated with a significantly lower incidence of saphenous vein graft failure (11.2%) per graft than was aspirin (20%; difference, -8.7% [95% CI, -13.5% to -3.9%]; OR, 0.51 [95% CI, 0.35 to 0.74]; P < .001) and was associated with a significantly lower incidence of saphenous vein graft failure per patient (13.2% vs 23.0%, difference, -9.7% [95% CI, -14.9% to -4.4%]; OR, 0.51 [95% CI, 0.35 to 0.74]; P < .001). Ticagrelor DAPT (22.1%) was associated with a significantly higher incidence of BARC type 2, 3, or 5 bleeding events than was aspirin (8.7%; difference, 13.3% [95% CI, 8.6% to 18.0%]; OR, 2.98 [95% CI, 1.99 to 4.47]; P < .001), but not BARC type 3 or 5 bleeding events (1.8% vs 1.8%, difference, 0% [95% CI, -1.8% to 1.8%]; OR, 1.00 [95% CI, 0.37 to 2.69]; P = .99). Compared with aspirin, ticagrelor monotherapy was not significantly associated with saphenous vein graft failure (19.3% vs 21.7%, difference, -2.6% [95% CI, -9.1% to 3.9%]; OR, 0.86 [95% CI, 0.58 to 1.27]; P = .44) or BARC type 2, 3, or 5 bleeding events (8.9% vs 7.3%, difference, 1.7% [95% CI, -2.8% to 6.1%]; OR, 1.25 [95% CI, 0.69 to 2.29]; P = .46). Conclusions and Relevance: Among patients undergoing coronary artery bypass graft surgery, adding ticagrelor to aspirin was associated with a significantly decreased risk of vein graft failure. However, this was accompanied by a significantly increased risk of clinically important bleeding.
Importance: The role of ticagrelor with or without aspirin after coronary artery bypass graft surgery remains unclear. Objective: To compare the risks of vein graft failure and bleeding associated with ticagrelor dual antiplatelet therapy (DAPT) or ticagrelor monotherapy vs aspirin among patients undergoing coronary artery bypass graft surgery. Data Sources: MEDLINE, Embase, and Cochrane Library databases from inception to June 1, 2022, without language restriction. Study Selection: Randomized clinical trials (RCTs) comparing the effects of ticagrelor DAPT or ticagrelor monotherapy vs aspirin on saphenous vein graft failure. Data Extraction and Synthesis: Individual patient data provided by each trial were synthesized into a combined data set for independent analysis. Multilevel logistic regression models were used. Main Outcomes and Measures: The primary analysis assessed the incidence of saphenous vein graft failure per graft (primary outcome) in RCTs comparing ticagrelor DAPT with aspirin. Secondary outcomes were saphenous vein graft failure per patient and Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding events. A supplementary analysis included RCTs comparing ticagrelor monotherapy with aspirin. Results: A total of 4 RCTs were included in the meta-analysis, involving 1316 patients and 1668 saphenous vein grafts. Of the 871 patients in the primary analysis, 435 received ticagrelor DAPT (median age, 67 years [IQR, 60-72 years]; 65 women [14.9%]; 370 men [85.1%]) and 436 received aspirin (median age, 66 years [IQR, 61-73 years]; 63 women [14.5%]; 373 men [85.5%]). Ticagrelor DAPT was associated with a significantly lower incidence of saphenous vein graft failure (11.2%) per graft than was aspirin (20%; difference, -8.7% [95% CI, -13.5% to -3.9%]; OR, 0.51 [95% CI, 0.35 to 0.74]; P < .001) and was associated with a significantly lower incidence of saphenous vein graft failure per patient (13.2% vs 23.0%, difference, -9.7% [95% CI, -14.9% to -4.4%]; OR, 0.51 [95% CI, 0.35 to 0.74]; P < .001). Ticagrelor DAPT (22.1%) was associated with a significantly higher incidence of BARC type 2, 3, or 5 bleeding events than was aspirin (8.7%; difference, 13.3% [95% CI, 8.6% to 18.0%]; OR, 2.98 [95% CI, 1.99 to 4.47]; P < .001), but not BARC type 3 or 5 bleeding events (1.8% vs 1.8%, difference, 0% [95% CI, -1.8% to 1.8%]; OR, 1.00 [95% CI, 0.37 to 2.69]; P = .99). Compared with aspirin, ticagrelor monotherapy was not significantly associated with saphenous vein graft failure (19.3% vs 21.7%, difference, -2.6% [95% CI, -9.1% to 3.9%]; OR, 0.86 [95% CI, 0.58 to 1.27]; P = .44) or BARC type 2, 3, or 5 bleeding events (8.9% vs 7.3%, difference, 1.7% [95% CI, -2.8% to 6.1%]; OR, 1.25 [95% CI, 0.69 to 2.29]; P = .46). Conclusions and Relevance: Among patients undergoing coronary artery bypass graft surgery, adding ticagrelor to aspirin was associated with a significantly decreased risk of vein graft failure. However, this was accompanied by a significantly increased risk of clinically important bleeding.
Authors: Mario Gaudino; Charalambos Antoniades; Umberto Benedetto; Saswata Deb; Antonino Di Franco; Gabriele Di Giammarco; Stephen Fremes; David Glineur; Juan Grau; Guo-Wei He; Daniele Marinelli; Lucas B Ohmes; Carlo Patrono; John Puskas; Robert Tranbaugh; Leonard N Girardi; David P Taggart Journal: Circulation Date: 2017-10-31 Impact factor: 29.690
Authors: Roxana Mehran; Sunil V Rao; Deepak L Bhatt; C Michael Gibson; Adriano Caixeta; John Eikelboom; Sanjay Kaul; Stephen D Wiviott; Venu Menon; Eugenia Nikolsky; Victor Serebruany; Marco Valgimigli; Pascal Vranckx; David Taggart; Joseph F Sabik; Donald E Cutlip; Mitchell W Krucoff; E Magnus Ohman; Philippe Gabriel Steg; Harvey White Journal: Circulation Date: 2011-06-14 Impact factor: 29.690
Authors: Lesley A Stewart; Mike Clarke; Maroeska Rovers; Richard D Riley; Mark Simmonds; Gavin Stewart; Jayne F Tierney Journal: JAMA Date: 2015-04-28 Impact factor: 56.272
Authors: Michael E Bowdish; Richard S D'Agostino; Vinod H Thourani; Thomas A Schwann; Carole Krohn; Nimesh Desai; David M Shahian; Felix G Fernandez; Vinay Badhwar Journal: Ann Thorac Surg Date: 2021-03-29 Impact factor: 4.330
Authors: Miguel Sousa-Uva; Franz-Josef Neumann; Anders Ahlsson; Fernando Alfonso; Adrian P Banning; Umberto Benedetto; Robert A Byrne; Jean-Philippe Collet; Volkmar Falk; Stuart J Head; Peter Jüni; Adnan Kastrati; Akos Koller; Steen D Kristensen; Josef Niebauer; Dimitrios J Richter; Petar M Seferovic; Dirk Sibbing; Giulio G Stefanini; Stephan Windecker; Rashmi Yadav; Michael O Zembala Journal: Eur J Cardiothorac Surg Date: 2019-01-01 Impact factor: 4.191
Authors: Jacqueline Saw; Graham C Wong; John Mayo; Victoria Bernstein; G B John Mancini; Jian Ye; Peter Skarsgard; Andrew Starovoytov; John Cairns Journal: Heart Date: 2016-02-18 Impact factor: 5.994
Authors: Paul W A Janssen; Joyce Peper; Laura M Willemsen; Mohamed A Soliman-Hamad; Albert H M van Straten; Patrick Klein; Chris M Hackeng; Uday Sonker; Margreet W A Bekker; Clemens von Birgelen; Marc A Brouwer; Pim van der Harst; Eline A Vlot; Vera H M Deneer; Dean R P P Chan Pin Yin; Marieke E Gimbel; Kasper F Beukema; Edgar J Daeter; Johannes C Kelder; Jan G P Tijssen; Benno J W M Rensing; Hendrik W van Es; Martin J Swaans; Jurrien M Ten Berg Journal: Circulation Date: 2020-08-31 Impact factor: 29.690
Authors: Fausto Biancari; Antonio Salsano; Francesco Santini; Marisa De Feo; Magnus Dalén; Qiyao Zhang; Giuseppe Gatti; Enzo Mazzaro; Ilaria Franzese; Ciro Bancone; Marco Zanobini; Tuomas Tauriainen; Timo Mäkikallio; Matteo Saccocci; Alessandra Francica; Stefano Rosato; Zein El-Dean; Francesco Onorati; Giovanni Mariscalco Journal: J Clin Med Date: 2022-09-28 Impact factor: 4.964